Adherence and forgiveness of two modern ART regimens: lamivudine/dolutegravir and emtricitabine/tenofovir alafenamide/rilpivirine.

IF 2.9 3区医学 Q3 IMMUNOLOGY

JAIDS Journal of Acquired Immune Deficiency Syndromes Pub Date : 2025-01-02 DOI:10.1097/QAI.0000000000003594

Taramasso L, Maggiolo F, Valenti D, Blanchi S, Centorrino F, Comi L, Di Biagio A

{"title":"Adherence and forgiveness of two modern ART regimens: lamivudine/dolutegravir and emtricitabine/tenofovir alafenamide/rilpivirine.","authors":"Taramasso L, Maggiolo F, Valenti D, Blanchi S, Centorrino F, Comi L, Di Biagio A","doi":"10.1097/QAI.0000000000003594","DOIUrl":null,"url":null,"abstract":"Introduction: Few data are available about the forgiveness of two-drug (2DR) or low-barrier three-drug antiretroviral regimens. The aim of this study is to evaluate the real-life forgiveness of lamivudine/dolutegravir (3TC/DTG) and emtricitabine/tenofovir alafenamide/rilpivirine (FTC/TAF/RPV).Methods: A two center retrospective observational study enrolled all people with HIV (PWH) treated with 3TC/DTG or FTC/TAF/RPV. Adherence was measured as the proportion of days covered (PDC) by drug supply. Binary logistic regression was applied to test the impact of baseline variables and adherence on the achievement of virological suppression.Results: 1258 adult PWH were enrolled, 368 in 3TC/DTG and 890 in RPV/F/TAF. Most were males (71 %), with median age of 51 years (IQR 43-58 years) and median CD4 nadir of 305 cells/mcL (IQR 132-485). The median cohort follow-up totaled 4558 persons/year. Median adherence, as calculated from PDC, was of 0.98 (IQR 0.93-1). Irrespective of the treatment group, a PDC as low as 0.8 was sufficient to obtain HIV-RNA below 200 copies/mL in almost all study participants. The same adherence value also allowed the achievement of HIV-RNA below 50 copies/mL in > 90% of study participants. PDC (P < 0.0001), Italian origin (P < 0.0001) and male sex (P = 0.038) significantly correlated to the achievement of < 200 copies/mL.Conclusions: In this study, we found a similar and high grade of forgiveness in the INSTI-based 2-drug regimen 3TC/DTG and in the NNRTI-based 3-drug regimen FTC/TAF/RPV.","PeriodicalId":14588,"journal":{"name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAIDS Journal of Acquired Immune Deficiency Syndromes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/QAI.0000000000003594","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Few data are available about the forgiveness of two-drug (2DR) or low-barrier three-drug antiretroviral regimens. The aim of this study is to evaluate the real-life forgiveness of lamivudine/dolutegravir (3TC/DTG) and emtricitabine/tenofovir alafenamide/rilpivirine (FTC/TAF/RPV).

Methods: A two center retrospective observational study enrolled all people with HIV (PWH) treated with 3TC/DTG or FTC/TAF/RPV. Adherence was measured as the proportion of days covered (PDC) by drug supply. Binary logistic regression was applied to test the impact of baseline variables and adherence on the achievement of virological suppression.

Results: 1258 adult PWH were enrolled, 368 in 3TC/DTG and 890 in RPV/F/TAF. Most were males (71 %), with median age of 51 years (IQR 43-58 years) and median CD4 nadir of 305 cells/mcL (IQR 132-485). The median cohort follow-up totaled 4558 persons/year. Median adherence, as calculated from PDC, was of 0.98 (IQR 0.93-1). Irrespective of the treatment group, a PDC as low as 0.8 was sufficient to obtain HIV-RNA below 200 copies/mL in almost all study participants. The same adherence value also allowed the achievement of HIV-RNA below 50 copies/mL in > 90% of study participants. PDC (P < 0.0001), Italian origin (P < 0.0001) and male sex (P = 0.038) significantly correlated to the achievement of < 200 copies/mL.

Conclusions: In this study, we found a similar and high grade of forgiveness in the INSTI-based 2-drug regimen 3TC/DTG and in the NNRTI-based 3-drug regimen FTC/TAF/RPV.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

JAIDS Journal of Acquired Immune Deficiency Syndromes 医学-传染病学

CiteScore

5.80

自引率

5.60%

发文量

490

审稿时长

3-6 weeks

期刊介绍： JAIDS: Journal of Acquired Immune Deficiency Syndromes seeks to end the HIV epidemic by presenting important new science across all disciplines that advance our understanding of the biology, treatment and prevention of HIV infection worldwide. JAIDS: Journal of Acquired Immune Deficiency Syndromes is the trusted, interdisciplinary resource for HIV- and AIDS-related information with a strong focus on basic and translational science, clinical science, and epidemiology and prevention. Co-edited by the foremost leaders in clinical virology, molecular biology, and epidemiology, JAIDS publishes vital information on the advances in diagnosis and treatment of HIV infections, as well as the latest research in the development of therapeutics and vaccine approaches. This ground-breaking journal brings together rigorously peer-reviewed articles, reviews of current research, results of clinical trials, and epidemiologic reports from around the world.